More on cancer study with RA drugs | Arthritis Information

Meanwhile, Abbott's epilepsy drug Depakote and other drugs in its class could face new warnings on their labels about possible risks of suicidal behavior. The FDA said Wednesday that it was evaluating the best way to communicate potential risks.

The North Chicago-based company said it has not heard reports of cancer risks from Humira or of suicidal thoughts in patients who have taken Depakote, but it is committed to working with the FDA in its evaluations of its drugs.

"There have been no incidents of lymphoma" reported in Humira patients, Abbott spokeswoman Laureen Cassidy said.

Humira, Abbott's top-selling drug, generated billion in worldwide sales last year. Depakote, the company's No. 2 product last year, generated .6 billion in sales. Combined, the two products accounted for about 18 percent of the company's worldwide sales of billion in 2007. The FDA said it is investigating about 30 reports of cancer during the past 10 years in children and young adults taking so-called TNF blockers such as Humira.

"The drugs Enbrel, Humira, and Remicade are being reviewed for a possible association between their use and the development of lymphoma and other cancers in children and young adults treated with TNF blockers for juvenile idiopathic arthritis and Crohn's disease," the FDA said. "Lymphoma is a cancer of the cells in the immune system."

Such drugs are predominantly used to treat rheumatoid arthritis, the most debilitating form of the disease. The bulk of sales of such drugs for Abbott and other makers come from treatments for adults, according to industry reports. It is unclear what, if any impact, the FDA's safety review would have on sales.

Abbott shares rose 27 cents, to .

Meanwhile, the FDA would not comment further about any labeling changes for Depakote or other epilepsy drugs, which also include Pfizer Inc.'s Lyrica and Johnson & Johnson's Topamax.

"The FDA has been carefully reviewing data on drugs used to treat epilepsy and is working on finding the most appropriate ways to convey to the public the risks of suicidality that were seen in trials," agency spokeswoman Sandy Walsh said. The FDA is "trying to figure out specific next steps, which may include drug-labeling changes and the convening of an advisory committee meeting," she said.

"Abbott's review of its clinical trial data showed no incremental risks of suicidal events with Depakote," Cassidy said. "Given the importance of this information for physicians, Abbott will work to implement any class recommendations recommended by the agency."

bjapsen@tribune.com